To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
Status:
Unknown status
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label, sing-arm, single site, phase IV clinical study. The main objective is
to evaluate the efficacy of afatinib in LSQC patients with EGFR sensitive mutation, and to
explore the clinical factors which might be predictive for the effectiveness in LSQC.